| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Adult |
| State: | Solid |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
In vitro, pirfenidone can inhibit the proliferation of uterine leiomyoma cells and leiomyoma cells. Pirfenidone inhibits the formation of collagen in TGF-β-1-induced fibroblasts. FGF and TGF-β-1 induced fibroblast proliferation. In the hamster model, pirfenidone, orally, prevents and treat bleomycin-induced pulmonary fibrosis. Pirfenidone can prevent chemically induced rat sclerosing peritonitis and can also be treated with keloid transplantation for nude mice.
Pirrenidone 0.01 1 mg / ml can inhibit the matrix and dose-dependent manner of serum stimulation of uterine fibroids and leiomyoma cell DNA synthesis, the compound without cytotoxicity, the collagen mRNA levels have no effect. Pirfenidone in the hamster pulmonary fibrosis model can reduce the level of collagen I mRNA levels before the disease, reduce lung proline levels and malondialdehyde and lung preservation of amino acid hydroxylase activity.
Pirfenidone is an antiinflammatory drug used to treat idiopathic pulmonary fibrosis. Anti-fibrosis agents, effective lung and pulmonary fibrosis models. Inhibit collagen production and fibroblast proliferation. Regulate the level of cytokines after oral administration of the body. Free radical scavengers and lipid peroxidation inhibitors. Pirfenidone inhibits collagen production and fibroblast proliferation. Antibacterial and antiinflammatory properties have been shown in various pulmonary fibrosis animal models and in clinical trials.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}